Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hung-Chih Hsu1,2, Nina Lapke3, Shu-Jen Chen4

  • 1Division of Hematology/Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan City 333, Taiwan. dannyhsuyoyo@gmail.com.

Cancers
|September 12, 2018
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A quasi-bridge to surgery approach for stage IV obstructive colon cancer: extending the bridge-to-surgery concept to metastatic disease.

World journal of surgical oncology·2026
Same author

Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus.

Therapeutic advances in medical oncology·2026
Same author

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same author

Trifluridine/tipiracil and survival in mismatch repair-deficient metastatic colorectal cancer.

Therapeutic advances in medical oncology·2026
Same author

Amivantamab Monotherapy in Chemorefractory <i>RAS</i>/<i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Response assessment in rectal cancer undergoing total neoadjuvant therapy: decision tree analysis integrating contrast enhanced T1-weighted MRI.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026
Summary
This summary is machine-generated.

Deleterious alterations in PTPRT and PTPRD genes are linked to bevacizumab resistance in colorectal cancer patients. These genetic changes may serve as predictive biomarkers for treatment response.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Bevacizumab is a standard treatment for colorectal cancer.
  • Predictive markers for bevacizumab response are lacking.

Purpose of the Study:

  • To identify genomic markers predictive of bevacizumab response in metastatic colorectal cancer.

Main Methods:

  • Next-generation sequencing of over 400 genes in tumor samples from 36 patients.
  • Analysis of single genes and signaling pathways to correlate genomic data with treatment response.

Main Results:

  • Deleterious mutations in PTPRT, a JAK/STAT signaling phosphatase, were enriched in non-responders.
  • Mutations in PTPRT and PTPRD correlated with bevacizumab resistance and shorter progression-free survival.
Keywords:
PTPRT/PTPRD mutation and deletionVEGFbevacizumab resistancemetastatic colorectal cancernext-generation sequencing

Related Experiment Videos

  • Alterations in RTK/PI3K/RAS, Wnt, and TGFβ pathways did not associate with response.

    • Conclusions:

    • Deleterious alterations in PTPRT/PTPRD are potential biomarkers for predicting bevacizumab resistance in colorectal cancer.